Industry News
Pharmaceutical Industry News
A combination of Merck-partnered…
A combination of Merck-partnered sac-TMT and Keytruda led to a “statistically significant and clinically meaningful” improvement in progression-free survival versus Keytruda alone in a phase 3 trial in first-line PD-L1-positive NSCLC, Kelun said Monday.
Cada vez más adolescentes toman antidepresivos. Podrían alterar su vida sexual por años
Los estudios sobre adultos que toman ISRS muestran que estos medicamentos reducen la libido. ¿Por qué no se analiza lo que esto podría significar para los chicos?
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone.
Eli Lilly’s latest high-profile…
Eli Lilly's latest high-profile crossovers—which include a starry TV partnership and the far-reaching rollout of a new campaign—both tie into the drugmaker’s work to draw more attention to Alzheimer’s disease.
Maryland is becoming the home away…
Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to increase its manufacturing
ACS CAN’s Pam Traxel joins…
ACS CAN’s Pam Traxel joins Health@WPP’s Wendy Lund to unpack what patients need most amid growing complexity in cancer care.
The approval came “months earlier…
The approval came "months earlier than anticipated," Pfizer's Chief Oncology Officer, Jeff Legos, Ph.D., said in a statement.
The FDA has opened an…
The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug.
Cosette had been attempting to…
Cosette had been attempting to invalidate its $430 million buyout of Australia's Mayne Pharma since May and has now seen its wish granted based on a national security concern from the Australian government.
Some four years into Jemperli’s…
Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio.
A Novo Nordisk challenge has…
A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against companies selling versions of its GLP-1 blockbuster.
The commercial effects of an…
The commercial effects of an emboldened anti-vaccine movement in the U.S. were evident in the third quarter as several companies reported declining vaccine sales.
Changes to a public health webpage…
Changes to a public health webpage undercut the medical community's consensus rebuke of childhood vaccines as a cause of autism. They were swiftly condemned by public health advocates and the Senate's top healthcare legislator.
In an effort to break even by…
In an effort to break even by 2028, mRNA specialist Moderna is laying out a three-year business strategy, highlighting promising avenues for growth and setting out a goal to lift revenue by up to 10%
A new report finds China supplies…
A new report finds China supplies many key pharmaceutical ingredients to the U.S. market. Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius Biotech scored FDA approval. And
Sun Pharma has launched an…
Sun Pharma has launched an eye-opening awareness push about a common—and commonly overlooked—complication of diabetes.
Pfizer and manufacturer Tris…
Pfizer and manufacturer Tris Pharma were accused in 2023 of previously providing ADHD med Quillivant through the Texas Medicaid program despite knowing that the drug failed quality control tests during production.
After months of back-and-forth…
After months of back-and-forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing option for the eye disease drug.
Cdymax Pharma has been slapped…
Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls.
New Gene-Editing Strategy Could Help Development of Treatments for Rare Diseases
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases.